Codexis Shows Enzymatic siRNA Synthesis Scale-Up

New TIDES Europe data point to higher product quality, faster cycle times, and greater siRNA potency from the company's ECO Synthesis platform.

Updated on Nov. 9, 2026 in Biotech

Codexis Shows Enzymatic siRNA Synthesis Scale-Up

Codexis presented data at TIDES Europe 2026 on its ECO Synthesis Manufacturing Platform, an aqueous enzymatic process being developed as an alternative to solid phase organic synthesis of oligonucleotides. The company reported product quality above 90% and a nearly halved cycle time at the 100-gram scale.

Why it matters

Traditional solid phase organic synthesis is the established route for producing oligonucleotides such as siRNA, and an enzymatic alternative that holds performance across a wide range of scales could change how these molecules are manufactured. The reported potency gain in human hepatocyte models also suggests the process may affect the biological performance of the final product.

Codexis reported product quality above 90% and cycle time nearly halved at the 100-gram scale, with performance maintained across three orders of magnitude in scale. The hepatocyte potency comparison comes from initial data in an ongoing study, and no clinical or in vivo results were presented.

The players

Codexis, Inc.

Codexis is a biotechnology company headquartered in Redwood City, California, that trades on NASDAQ under the symbol CDXS and develops enzyme-based manufacturing processes.

The details

Codexis presented new ECO Synthesis capabilities for efficient incorporation of tissue-targeting moieties and shared initial biological data from an ongoing structure-activity relationship study. The company is advancing the aqueous enzymatic process toward industrialization, and its enzymes are said to drive higher yields, increased purity, and reduced energy usage and waste generation.

Timeline

  1. November 9, 2026: Codexis issued a press release announcing the TIDES Europe data.

  2. 2026: Codexis presented the ECO Synthesis data at TIDES Europe 2026 in Europe.

Tech Race

Codexis is positioning its aqueous enzymatic ECO Synthesis process as an alternative to solid phase organic synthesis, the incumbent route for making oligonucleotides like siRNA. The company is working to move the platform toward industrialization, so its scale and cost claims will be tested against that established chemical method.

For people who take siRNA-based therapies, a manufacturing route that improves purity and cuts cycle time could eventually affect cost and availability, though the source gives no timeline for that. The reported potency gain would matter to patients only if it carries into clinical results, which have not been presented.

The takeaway

Enzymatic manufacturing of oligonucleotides is being tested at increasing scale, with early data pointing to better quality and speed. Whether those gains hold up in clinical use remains to be shown.

Further reading

For broader context on the field, explore Biotech coverage on Wisevoter.

Source note: This article includes information reported by The Manila times.